We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson (BDX) Beats On Earnings & Revenues In Q2
Read MoreHide Full Article
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #2 (Buy) but that could change following its second-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 7 cents and increased 5.5% from $2.18 posted in the year-ago quarter.
Revenues:Adjusted revenues amounted to $2.969 billion, down 3.2% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $2.921 billion.
Becton, Dickinson and Company Price and EPS Surprise
Key Stats: BD Medical generated revenues of $1.987 billion, down 6.8% on a year-over-year basis. BD Life sciences generated revenues of $982 million, up 4.9% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 4%.
Major Factors: Impressive results in the company’s medical segment reflect strong performance in the Medication and Procedural Solutions and Medication Management Solutions units.Notably, within the Medication Management Solutions unit, the Company made some changes to its U.S. dispensing business model.
Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
Image: Bigstock
Becton, Dickinson (BDX) Beats On Earnings & Revenues In Q2
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #2 (Buy) but that could change following its second-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 7 cents and increased 5.5% from $2.18 posted in the year-ago quarter.
Revenues:Adjusted revenues amounted to $2.969 billion, down 3.2% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $2.921 billion.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote
Key Stats: BD Medical generated revenues of $1.987 billion, down 6.8% on a year-over-year basis. BD Life sciences generated revenues of $982 million, up 4.9% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 4%.
Major Factors: Impressive results in the company’s medical segment reflect strong performance in the Medication and Procedural Solutions and Medication Management Solutions units.Notably, within the Medication Management Solutions unit, the Company made some changes to its U.S. dispensing business model.
Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks ""Strong Sells"" absolutely free >>